Rheumatology Network's Top 5: October 8, 2022

Published on: 

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 8, 2022.

Real-World Findings Support Increased Pegloticase and Immunomodulation Co-Therapy Response Rates in Gout

“Importantly, several different immunomodulation agents may be effective for increasing treatment response rates and seem well tolerated by patients with uncontrolled gout."

Fibromyalgia Negatively Impacts Functionality, Quality of Life in Female Patients

Results underline the importance of psychiatric evaluation and treatment in patients with fibromyalgia.

COVID-19 Vaccination Rates in Patients with SLE Comparable to Matched Controls

"Surveys of patients with SLE and other autoimmune and inflammatory rheumatic diseases have identified vaccine hesitancy in up to 50% of patients, which may be related to concerns about side effects, potential disease flares, or lack of data among patients with SLE.”

CAR T Cell Therapy Offers a New Hope in the Treatment of Severe and Refractory Systemic Lupus Erythematosus

The findings of this study of anti-CD19 directed CAR T cell therapy offers new hope for the most severe and refractory cases.

Higher Prevalence of Sarcopenia Reported in Patients with Rheumatoid Arthritis

The single-center, cross-sectional study assessed chair rise time, gait speed, and grip strength to determine the prevalence of sarcopenia.